Company / Accounts Receivable
4D Molecular Therapeutics, Inc. Accounts Receivable History
FY2020-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$47.0K
FY2021
5-year range
$47.0K / $47.0K
FY2020-FY2021
Trend
-96.8%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$47,000 in FY2021.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, accounts receivable decreased 96.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $47.0K | -96.8% |
| FY2020 | $1.5M | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026